Latest & greatest articles for copd exacerbations

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd exacerbations or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on copd exacerbations and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for copd exacerbations

41. Randomised controlled trial: LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients

Randomised controlled trial: LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our (...) . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients Article Text

2016 Evidence-Based Medicine (Requires free registration)

42. Use of a procalcitonin algorithim to guide antimicrobial therapy in COPD exacerbations can reduce antibiotic consumption with no increase in rates of treatment failure or mortality

Use of a procalcitonin algorithim to guide antimicrobial therapy in COPD exacerbations can reduce antibiotic consumption with no increase in rates of treatment failure or mortality BestBets: Use of a procalcitonin algorithim to guide antimicrobial therapy in COPD exacerbations can reduce antibiotic consumption with no increase in rates of treatment failure or mortality Use of a procalcitonin algorithim to guide antimicrobial therapy in COPD exacerbations can reduce antibiotic consumption (...) of chronic obstructive pulmonary disease (COPD)] can [use of a procalcitonin algorithm compared to physician gestalt] result in [lower rates of antibiotic consumption with no adverse effects] Clinical Scenario A 78 year old female presents to your emergency department reporting increased wheezing over the last 24 hours. She reports a mildly productive cough and denies fever. A chest x-ray reveals no clear evidence of pneumonia. In addition to therapy for what you believe is a COPD exacerbation, you

2015 BestBETS

43. In patients presenting with an exacerbation of COPD can a normal venous blood gas pCO2 rule out arterial hypercarbia?

In patients presenting with an exacerbation of COPD can a normal venous blood gas pCO2 rule out arterial hypercarbia? BestBets: In patients presenting with an exacerbation of COPD can a normal venous blood gas pCO2 rule out arterial hypercarbia? In patients presenting with an exacerbation of COPD can a normal venous blood gas pCO2 rule out arterial hypercarbia? Report By: Mark Woods - Consultant in Emergency Medicine Search checked by David Hodgson - ST5 Emergency Medicine Institution: Whiston (...) Hospital, Merseyside, UK and Mersey School of Emergency Medicine, UK Date Submitted: 31st August 2012 Date Completed: 10th March 2015 Last Modified: 11th March 2015 Status: Green (complete) Three Part Question In [patients with an Acute Exacerbation of COPD] can a [normal venous blood gas CO2] [rule out arterial hypercarbia]? Clinical Scenario A 74 year old male patient with known COPD presents acutely breathless with widespread wheeze. He refuses an arterial blood gas (ABG) and complains that last

2015 BestBETS

44. Pulmonary Rehabilitation for Postacute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A Cost-Effectiveness and Budget Impact Analysis

Pulmonary Rehabilitation for Postacute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A Cost-Effectiveness and Budget Impact Analysis Pulmonary Rehabilitation for Postacute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A Cost-Effectiveness and Budget Impact Analysis. February 2015; pp. 1-47 Pulmonary Rehabilitation for Postacute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A Cost-Effectiveness and Budget Impact Analysis X XIE, M WANG, A SCHAINK (...) , M KRAHN FEBRUARY 2015 Pulmonary Rehabilitation for Postacute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A Cost-Effectiveness and Budget Impact Analysis. February 2015; pp. 1-47 Pulmonary Rehabilitation for Postacute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A Cost-Effectiveness and Budget Impact Analysis. February 2015; pp. 1-47 Pulmonary Rehabilitation for Postacute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A Cost-Effectiveness

2015 Health Quality Ontario

45. Executive Summary: Prevention of Acute Exacerbation of COPD

Executive Summary: Prevention of Acute Exacerbation of COPD 883 journal.publications.chestnet.org E x e c u t i v e S umm a r y Prevention of Acute Exacerbation of COPD: American College of Chest Physicians and Canadian Th oracic Society Guideline Gerard J. Criner , MD, FCCP ; Jean Bourbeau , MD, FCCP ; Rebecca L. Diekemper , MPH ; Daniel R. Ouellette , MD, FCCP ; Donna Goodridge , RN, PhD ; Paul Hernandez , MDCM ; Kristen Curren , MA ; Meyer S. Balter , MD, FCCP ; Mohit Bhutani , MD, FCCP (...) Medicine [ 147#4 CHEST APRIL 2015 ] health-care expenditures, $8.0 billion in indirect morbidity costs, and $12.4 billion in indirect mortality costs. 9 Exacerbations account for most of the morbidity, mortality, and costs associated with COPD. The economic burden associated with moderate and severe exacerbations in Canada has been estimated to be in the range of $646 million to $736 million per annum. 10 Th is value may be an underestimate given that the prevalence of moderate exacerbations

2015 American College of Chest Physicians

46. Prevention of Acute Exacerbations of COPD

Prevention of Acute Exacerbations of COPD 894 Evidence-Based Medicine [ 147#4 CHEST APRIL 2015 ] P r e v en tio n o f A c u t e Exacerba tio n s o f C O PD American College of Chest Physicians and Canadian Th oracic Society Guideline Gerard J. Criner , MD, FCCP ; Jean Bourbeau , MD, FCCP ; Rebecca L. Diekemper , MPH ; Daniel R. Ouellette , MD, FCCP ; Donna Goodridge , RN, PhD ; Paul Hernandez , MDCM ; Kristen Curren , MA ; Meyer S. Balter , MD, FCCP ; Mohit Bhutani , MD, FCCP ; Pat G. Camp (...) the rest of the world. An exacerbation of COPD (periodic escalations of symptoms of cough, dyspnea, and sputum production) is a major contributor to worsening lung function, impairment in quality of life, need for urgent care or hospitalization, and cost of care in COPD. Research conducted over the past decade has contributed much to our current understanding of the pathogenesis and treatment of COPD. Additionally, an evolving literature has accumu- lated about the prevention of acute exacerbations

2015 American College of Chest Physicians

47. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. (PubMed)

Withdrawal of inhaled glucocorticoids and exacerbations of COPD. Treatment with inhaled glucocorticoids in combination with long-acting bronchodilators is recommended in patients with frequent exacerbations of severe chronic obstructive pulmonary disease (COPD). However, the benefit of inhaled glucocorticoids in addition to two long-acting bronchodilators has not been fully explored.In this 12-month, double-blind, parallel-group study, 2485 patients with a history of exacerbation of COPD (...) received triple therapy consisting of tiotropium (at a dose of 18 μg once daily), salmeterol (50 μg twice daily), and the inhaled glucocorticoid fluticasone propionate (500 μg twice daily) during a 6-week run-in period. Patients were then randomly assigned to continued triple therapy or withdrawal of fluticasone in three steps over a 12-week period. The primary end point was the time to the first moderate or severe COPD exacerbation. Spirometric findings, health status, and dyspnea were also

Full Text available with Trip Pro

2014 NEJM

48. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. (PubMed)

Withdrawal of inhaled glucocorticoids and exacerbations of COPD. Treatment with inhaled glucocorticoids in combination with long-acting bronchodilators is recommended in patients with frequent exacerbations of severe chronic obstructive pulmonary disease (COPD). However, the benefit of inhaled glucocorticoids in addition to two long-acting bronchodilators has not been fully explored.In this 12-month, double-blind, parallel-group study, 2485 patients with a history of exacerbation of COPD (...) received triple therapy consisting of tiotropium (at a dose of 18 μg once daily), salmeterol (50 μg twice daily), and the inhaled glucocorticoid fluticasone propionate (500 μg twice daily) during a 6-week run-in period. Patients were then randomly assigned to continued triple therapy or withdrawal of fluticasone in three steps over a 12-week period. The primary end point was the time to the first moderate or severe COPD exacerbation. Spirometric findings, health status, and dyspnea were also

Full Text available with Trip Pro

2014 NEJM

49. Should you consider antibiotics for exacerbations of mild COPD?

Should you consider antibiotics for exacerbations of mild COPD? Should you consider antibiotics for exacerbations of mild COPD? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Should you consider antibiotics for exacerbations of mild COPD? View/ Open Date 2014-04 Format Metadata Abstract Consider antibiotics (...) for patients with exacerbations of mild to moderate chronic obstructive pulmonary disease (COPD). URI Part of Citation Journal of Family Practice, 64(4): 2014: E11-E13 Rights OpenAccess. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License. Collections hosted by hosted by

2014 PURLS

50. Short- and medium-term prognosis in patients hospitalized for COPD exacerbation: the CODEX index (PubMed)

Short- and medium-term prognosis in patients hospitalized for COPD exacerbation: the CODEX index No valid tools exist for evaluating the prognosis in the short and medium term after hospital discharge of patients with COPD. Our hypothesis was that a new index based on the CODEX (comorbidity, obstruction, dyspnea, and previous severe exacerbations) index can accurately predict mortality, hospital readmission, and their combination for the period from 3 months to 1 year after discharge (...) in patients hospitalized for COPD.A multicenter study of patients hospitalized for COPD exacerbations was used to develop the CODEX index, and a different patient cohort was used for validation. Comorbidity was measured using the age-adjusted Charlson index, whereas dyspnea, obstruction, and severe exacerbations were calculated according to BODEX (BMI, airfl ow obstruction, dyspnea, and previous severe exacerbations) thresholds. Information about mortality and readmissions for COPD or other causes

2014 EvidenceUpdates

51. 2014 CHEST-CTS Guideline: Prevention of Acute Exacerbation of COPD

2014 CHEST-CTS Guideline: Prevention of Acute Exacerbation of COPD ONLINE FIRST This is an Online First, unedited version of this article. The final, edited version will appear in a numbered issue of CHEST and may contain substantive changes. We encourage readers to check back for the final article. Online First papers are indexed in PubMed and by search engines, but the information, including the final title and author list, may be updated on final publication. http (...) morbidity costs and $12.4 billion in indirect mortality costs. 9 Exacerbations account for Page 5 of 28 Downloaded From: http://journal.publications.chestnet.org/ on 10/23/2014 5 most of the morbidity, mortality, and costs associated with COPD. The economic burden associated with moderate and severe exacerbations in Canada has been estimated in the range of $646 million to $736 million per annum. 10 This value may be an underestimate given that the prevalence of moderate exacerbations is not well

2014 Canadian Thoracic Society

52. Simvastatin for the Prevention of Exacerbations in Moderate-to-Severe COPD. (PubMed)

Simvastatin for the Prevention of Exacerbations in Moderate-to-Severe COPD. Retrospective studies have shown that statins decrease the rate and severity of exacerbations, the rate of hospitalization, and mortality in chronic obstructive pulmonary disease (COPD). We prospectively studied the efficacy of simvastatin in preventing exacerbations in a large, multicenter, randomized trial.We designed the Prospective Randomized Placebo-Controlled Trial of Simvastatin in the Prevention of COPD (...) Exacerbations (STATCOPE) as a randomized, controlled trial of simvastatin (at a daily dose of 40 mg) versus placebo, with annual exacerbation rates as the primary outcome. Patients were eligible if they were 40 to 80 years of age, had COPD (defined by a forced expiratory volume in 1 second [FEV1] of less than 80% and a ratio of FEV1 to forced vital capacity of less than 70%), and had a smoking history of 10 or more pack-years, were receiving supplemental oxygen or treatment with glucocorticoids

Full Text available with Trip Pro

2014 NEJM

53. Systematic review and meta-analysis: Long-term antibiotic therapy reduces exacerbation frequency in patients with COPD but it remains unclear which patients to target

Systematic review and meta-analysis: Long-term antibiotic therapy reduces exacerbation frequency in patients with COPD but it remains unclear which patients to target Long-term antibiotic therapy reduces exacerbation frequency in patients with COPD but it remains unclear which patients to target | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more (...) about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Long-term antibiotic therapy reduces exacerbation frequency in patients with COPD

2014 Evidence-Based Medicine (Requires free registration)

54. ACP Journal Club. Amoxicillin/clavulanate vs placebo: more exacerbation cures, fewer recurrences in mild-to-moderate COPD. (PubMed)

ACP Journal Club. Amoxicillin/clavulanate vs placebo: more exacerbation cures, fewer recurrences in mild-to-moderate COPD. 23552686 2013 05 13 2013 04 04 1539-3704 158 6 2013 Mar 19 Annals of internal medicine Ann. Intern. Med. ACP Journal Club. Amoxicillin/clavulanate vs placebo: more exacerbation cures, fewer recurrences in mild-to-moderate COPD. JC3 10.7326/0003-4819-158-6-201303190-02003 Adams Sandra G SG University of Texas Health Science Center at San Antonio and South Texas Veterans

2013 Annals of Internal Medicine

55. Comorbidities and Short-term Prognosis in Patients Hospitalized for Acute Exacerbation of COPD: The EPOC en Servicios de Medicina Interna (ESMI) Study (PubMed)

Comorbidities and Short-term Prognosis in Patients Hospitalized for Acute Exacerbation of COPD: The EPOC en Servicios de Medicina Interna (ESMI) Study Comorbidities are frequent in patients hospitalized for COPD exacerbation, but little is known about their relation with short-term mortality and hospital readmissions. Our hypothesis is that the frequency and type of comorbidities impair the prognosis within 12 weeks after discharge.A longitudinal, observational, multicenter study of patients (...) hospitalized for a COPD exacerbation with spirometric confirmation was performed. Comorbidity information was collected using the Charlson index and a questionnaire that included other common conditions not included in this index. Dyspnea, functional status, and previous hospitalization for COPD or other reasons among other variables were investigated. Information on mortality and readmissions for COPD or other causes was collected up to 3 months after discharge.We studied 606 patients, 594 men (89.9

2013 EvidenceUpdates

56. Herbal Therapy and Stable COPD: Delaying Onset and Duration of Acute Exacerbations with Supplementation to Baseline Therapy

Herbal Therapy and Stable COPD: Delaying Onset and Duration of Acute Exacerbations with Supplementation to Baseline Therapy "Herbal Therapy and Stable COPD: Delaying Onset and Duration of Acute E" by Amy M. Hernandez < > > > > > Title Author Date of Graduation Fall 10-18-2013 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Patients with chronic obstructive pulmonary disease (COPD) experience progressive pulmonary decline (...) with each acute exacerbation of disease. Current therapy is focused on treating acute symptoms of COPD, but there are no medications that have been implemented to delay the progression of the disease. Herbal therapies have been developed by researchers to supplement baseline therapy for COPD with the goal of prolonging healthful pulmonary states, thereby slowing disease progression. Methods: Exhaustive search of available medical literature from Medline, CINAHL, Web of Science, EBMR and NIH websites

2013 Pacific University EBM Capstone Project

57. Hospital-at-home programs for patients with acute exacerbations of chronic obstructive pulmonary disease (COPD): an evidence-based analysis

Hospital-at-home programs for patients with acute exacerbations of chronic obstructive pulmonary disease (COPD): an evidence-based analysis Hospital-at-home programs for patients with acute exacerbations of chronic obstructive pulmonary disease (COPD): an evidence-based analysis Hospital-at-home programs for patients with acute exacerbations of chronic obstructive pulmonary disease (COPD): an evidence-based analysis McCurdy BR Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation McCurdy BR. Hospital-at-home programs for patients with acute exacerbations of chronic obstructive pulmonary disease (COPD): an evidence-based analysis. Toronto: Medical Advisory Secretariat (MAS). Volume 12(10). 2012 Authors' objectives The objective of this analysis was to compare hospital-at-home care with inpatient hospital care for patients with acute

2012 Health Technology Assessment (HTA) Database.

58. Antibiotic Prevention of Acute Exacerbations of COPD. (PubMed)

Antibiotic Prevention of Acute Exacerbations of COPD. 22830464 2012 08 02 2012 11 08 1533-4406 367 4 2012 Jul 26 The New England journal of medicine N. Engl. J. Med. Antibiotic prevention of acute exacerbations of COPD. 340-7 10.1056/NEJMct1115170 Wenzel Richard P RP Department of Internal Medicine, Virginia Commonwealth University Medical Center, Richmond, USA. rwenzel@mcvh-vcu.edu Fowler Alpha A AA 3rd Edmond Michael B MB eng Journal Article Review United States N Engl J Med 0255562 0028-4793

Full Text available with Trip Pro

2012 NEJM

59. Dyspnoea severity and pneumonia as predictors of in-hospital mortality and early readmission in acute exacerbations of COPD (PubMed)

Dyspnoea severity and pneumonia as predictors of in-hospital mortality and early readmission in acute exacerbations of COPD Rates of mortality and readmission are high in patients hospitalised with acute exacerbations of chronic obstructive pulmonary disease (AECOPD). In this population, the prognostic value of the Medical Research Council Dyspnoea Scale (MRCD) is uncertain, and an extended MRCD (eMRCD) scale has been proposed to improve its utility. Coexistent pneumonia is common and, although (...) readmitted within 28 days of discharge. During their stable state prior to admission, 34.2% of patients were too breathless to leave the house. Mortality was significantly higher in pneumonic than in non-pneumonic exacerbations (20.1% vs 5.8%, p<0.001). eMRCD was a significantly better discriminator than either CURB-65 or the traditional MRCD scale for predicting in-hospital mortality, and was a stronger prognostic tool than CURB-65 in the subgroup of patients with pneumonic AECOPD.The severity

Full Text available with Trip Pro

2012 EvidenceUpdates

60. Validation of a novel risk score for severity of illness in acute exacerbations of COPD (PubMed)

Validation of a novel risk score for severity of illness in acute exacerbations of COPD Clinicians lack a validated tool for risk stratification in acute exacerbations of COPD (AECOPD). We sought to validate the BAP-65 (elevated BUN, altered mental status, pulse > 109 beats/min, age > 65 years) score for this purpose.We analyzed 34,699 admissions to 177 US hospitals (2007) with either a principal diagnosis of AECOPD or acute respiratory failure with a secondary diagnosis of AECOPD. Hospital

2012 EvidenceUpdates